Terri Lynn Parker, MD

Assistant Professor of Medicine (Hematology); Assistant Professor

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: Not Applicable

Patient Care Organizations

Cancer Center, Yale: Hematology Program

Hematology

Yale Medical Group

Board Certifications

  • Internal Medicine AB of Internal Medicine (2008)

  • Hospice & Palliative Medicine AB of Internal Medicine (2010)

  • Hematology (Internal Medicine) AB of Internal Medicine (2012)

Clinical Trials

Conditions Study Title
Unknown Sites Study of Immune System in Patients with Cancer and Blood Disorders
Non-Hodgkin's Lymphoma Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Unknown Sites Specimen Repository for Hematologic Diseases
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Multiple Myeloma Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
S1304, A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Myeloid and Monocytic Leukemia A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Myeloid and Monocytic Leukemia A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Multiple Myeloma A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Myeloid and Monocytic Leukemia A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Edit this profile

Contact Info

Terri Lynn Parker, MD
Patient Care Location
Yale Cancer CenterSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 7

New Haven, CT 06511
Mailing Address
PO Box 208028
New Haven, CT 06520-8021